David R Spriggs
Overview
Explore the profile of David R Spriggs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
83
Citations
2501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang S, Yan C, Millar D, Yang Q, Heather J, Langenbucher A, et al.
Cancer Res
. 2024 May;
84(9):1534.
PMID: 38693893
No abstract available.
2.
Al-Alem L, Prendergast J, Clark J, Zarrella B, Zarrella D, Hill S, et al.
J Ovarian Res
. 2024 Apr;
17(1):71.
PMID: 38566237
Background: Ovarian cancer remains the deadliest of the gynecologic cancers in the United States. There have been limited advances in treatment strategies that have seen marked increases in overall survival....
3.
Matoba Y, Zarrella D, Pooladanda V, Azimi Mohammadabadi M, Kim E, Kumar S, et al.
Br J Cancer
. 2024 Mar;
130(9):1463-1476.
PMID: 38438589
Background: Uterine serous cancer (USC) comprises around 10% of all uterine cancers. However, USC accounts for approximately 40% of uterine cancer deaths, which is attributed to tumor aggressiveness and limited...
4.
Lee K, Perry K, Xu M, Veillard I, Kumar R, Rao T, et al.
J Ovarian Res
. 2024 Feb;
17(1):41.
PMID: 38374055
Background: Mucin 16 (MUC16) overexpression is linked with cancer progression, metastasis, and therapy resistance in high grade serous ovarian cancer and other malignancies. The cleavage of MUC16 forms independent bimodular...
5.
Rao T, Xu M, Eng S, Yang G, Manson R, Rosales N, et al.
Mol Cancer Ther
. 2022 Apr;
21(5):775-785.
PMID: 35413118
Significant strides have been made in the development of precision therapeutics for cancer. Aberrantly expressed glycoproteins represent a potential avenue for therapeutic development. The MUC16/CA125 glycoprotein serves as a biomarker...
6.
Zhang S, Yan C, Millar D, Yang Q, Heather J, Langenbucher A, et al.
Cancer Res
. 2021 Dec;
82(5):773-784.
PMID: 34965933
Significance: This study develops a high-throughput preclinical platform to identify patient-specific antibody-peptide epitope conjugates that target cancer cells and demonstrates the potential of this immunotherapy approach for treating ovarian carcinoma.
7.
Russo A, Lee L, Wo J, Niemierko A, Park D, Alban G, et al.
Am J Clin Oncol
. 2021 Nov;
45(1):36-39.
PMID: 34817442
Objectives: The objective of this study was to determine if deficiency of mismatch repair (dMMR) proteins in patients with early-stage favorable endometrial cancer treated with vaginal brachytherapy (VB) is associated...
8.
Yang Z, Francisco J, Reese A, Spriggs D, Im H, Castro C
Biophys Rev (Melville)
. 2021 Apr;
2(1):011303.
PMID: 33842926
Almost all cases of cervical cancer are caused by the human papilloma virus (HPV). Detection of pre-cancerous cervical changes provides a window of opportunity for cure of an otherwise lethal...
9.
Stasenko M, Smith E, Yeku O, Park K, Laster I, Lee K, et al.
Sci Rep
. 2021 Feb;
11(1):3718.
PMID: 33580170
The lectin, galectin-3 (Gal3), has been implicated in a variety of inflammatory and oncogenic processes, including tumor growth, invasion, and metastasis. The interactions of Gal3 and MUC16 represent a potential...
10.
Shimada C, Xu R, Al-Alem L, Stasenko M, Spriggs D, Rueda B
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32486344
Ovarian cancer is known for its aggressive pathological features, including the capacity to undergo epithelial to mesenchymal transition, promoting angiogenesis, metastatic potential, chemoresistance, inhibiting apoptosis, immunosuppression and promoting stem-like features....